This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Oct;9(10):942-3.

doi: 10.1016/S1474-4422(10)70217-9. Epub 2010 Sep 15.

Secondary prevention of stroke: can we do better than aspirin?

Dharam J Kumbhani, Deepak L Bhatt

PMID: 20833590
DOI: 10.1016/S1474-4422(10)70217-9

Comment

Secondary prevention of stroke: can we do better than aspirin?

Dharam J Kumbhani et al. Lancet Neurol. 2010 Oct.

. 2010 Oct;9(10):942-3.

doi: 10.1016/S1474-4422(10)70217-9. Epub 2010 Sep 15.

Authors

Dharam J Kumbhani, Deepak L Bhatt

PMID: 20833590
DOI: 10.1016/S1474-4422(10)70217-9

No abstract available

PubMed Disclaimer

Comment on

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group. Shinohara Y, et al. Lancet Neurol. 2010 Oct;9(10):959-68. doi: 10.1016/S1474-4422(10)70198-8. Epub 2010 Sep 15. Lancet Neurol. 2010. PMID: 20833591 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science